$1.5 Million to Support a Clinical Trial on Hematologic Cancers
The Cancer Research Society (CRS) is pleased to announce a major investment of $1.5 million to support the clinical trial led by the eminent hematologist Dr. Denis-Claude Roy. This project, titled GLIDE (Guided Lymphocyte Immunopeptide Derived Expansion), represents a significant advancement in the treatment of hematologic cancers.
Bone marrow transplantation is recommended for certain aggressive forms of blood cancers, or when conventional treatments like chemotherapy are ineffective. This procedure involves injecting donor bone marrow cells to eliminate cancerous cells in a patient. However, this method has limitations, such as cases of relapse or the injection of certain donor cells attacking the patient’s healthy tissues, leading to serious complications.
To overcome these obstacles, Dr. Roy’s team at Maisonneuve-Rosemont Hospital is developing cutting-edge transplant technology. This precision medicine approach aims to identify a suitable healthy donor, select and activate donor cells capable of recognizing and eliminating specifically cancer cells, multiply them in the laboratory, and then inject these cells into the patient. The overall goal of this pioneering clinical trial is to reduce the risk of complications and increase treatment efficiency.
– Manon Pepin, President and CEO of CRS
“This funding is crucial to allow us to continue advancing our research and bring innovative treatments to patients. We are extremely grateful. The GLIDE project represents an important step towards the future of precision medicine, with the aim of saving more lives and offering new hope to those who need it most.”
– Dr. Denis-Claude Roy, Director of the Hematology-Oncology and Cell Therapy University Institute, Maisonneuve-Rosemont Hospital
The Cancer Research Society also wishes to thank Herbert and Ronald Black for their generous donation, which was essential to support this clinical trial.
“We are deeply honored to be able to support such a revolutionary project. We have great confidence in the potential of this clinical trial to transform the treatment of blood cancers and to offer a new chance at life to many patients.”
– Herbert and Ronald Black
While maintaining its traditional investment in fundamental research, CRS is now expanding its support to clinical research by funding trials led by researchers. Through innovative projects like GLIDE, we are moving towards a future where treatments will be more effective and less risky, aiming to outsmart cancer.